Themes · Obesity_weight_loss

Narrative basket·№4 of the day·As of 2026-08-25

Obesity & Weight-Loss Therapeutics/ №4

Obesity and weight-loss therapeutics and direct treatment exposure.

As of 2026-08-25, Obesity & Weight-Loss Therapeutics ranks №4 among themes for that session with a composite score of 64/100 and median member RS of 80.

Composite: 64_/100
Median RS: 80
Breadth > 50dma: 67%
% at Highs: 38%
Accumulation: 44%
$-Vol Δ: -9%

Score history · last 60 sessionsLast 64·Range 33–70

Members_{19 tickers}

Ticker / whyRSTrendHighAccum$Vol

MBXMBX is clinically developing MBX 4291, a long-acting GLP-1/GIP co-agonist prodrug, for obesity and reports a broader obesity portfolio.

RS 98

50D

-42%$18.8M$32.7M

ARWRArrowhead is clinically developing ARO-INHBE and ARO-ALK7 as RNAi therapeutics for obesity and reports human obesity-study activity.

RS 97

50D

HIGH

-19%$87.3M$108.2M

MRKMerck holds an exclusive global license to develop, manufacture, and commercialize MK-4082 (HS-10535), a preclinical oral GLP-1 receptor agonist whose official license announcement identifies weight reduction and potential additional cardiometabolic benefits.

RS 88

50D

HIGH

+44%$2.2B$1.5B

GPCRStructure Therapeutics' lead candidate aleniglipron is an oral GLP-1 receptor agonist in Phase 2 development for obesity and chronic weight management.

RS 88

-26%$23.2M$31.5M

SRRKScholar Rock reports clinical and preclinical programs aimed at preserving lean mass during GLP-1-induced weight loss in people with obesity.

RS 83

50D

HIGH

ACCUM

+26%$70.5M$56.0M

AZNAstraZeneca's current pipeline lists multiple chronic-weight-management and obesity assets, including AZD6234 and combination incretin/amylin programs.

RS 82

-17%$585.9M$708.2M

AMGNAmgen is running Phase 3 chronic-weight-management studies of MariTide, a GLP-1/GIP-pathway antibody-peptide conjugate.

RS 82

50D

HIGH

ACCUM

-18%$929.1M$1.1B

CRBPCorbus is developing CRB-913, an oral CB1 inverse agonist, specifically for obesity and has an active clinical study.

RS 80

50D

ACCUM

+252%$14.5M$4.1M

LLYEli Lilly markets Zepbound for chronic weight management and develops additional incretin and obesity medicines.

RS 79

50D

-23%$2.6B$3.4B

HIMSHims & Hers operates a consumer-health platform with weight-loss offerings and access to branded and limited compounded GLP-1 products.

RS 78

ACCUM

-29%$305.8M$428.5M

REGNRegeneron's pipeline lists trevogrumab in Phase 2 obesity work focused on preserving muscle during weight loss.

RS 76

50D

HIGH

ACCUM

-34%$421.1M$636.7M

VKTXViking is advancing injectable and oral VK2735 through late-stage trials for obesity and chronic weight management.

RS 58

+13%$71.6M$63.6M

PFEPfizer acquired Metsera in November 2025, adding clinical-stage obesity and cardiometabolic candidates including MET-097i and MET-233i programs.

RS 58

50D

HIGH

ACCUM

-15%$911.1M$1.1B

NVONovo Nordisk markets Wegovy and other GLP-1 products and maintains extensive obesity and weight-management development programs.

RS 52

50D

ACCUM

+13%$756.1M$667.9M

BIOABioAge reports planned obesity proof-of-concept work for BGE-102 and preclinical APJ-agonist obesity programs after discontinuing azelaprag.

RS 45

-67%$5.0M$15.3M

ALTAltimmune's April 2026 Form 424B5 explicitly states that pemvidutide is in clinical development for obesity and MASH and describes the candidate as optimized for both, with clinical weight-loss results.

RS 29

50D

-28%$12.2M$16.9M

RANIRani is clinically developing oral RT-114, a GLP-1/GLP-2 dual agonist delivered by the RaniPill capsule, for obesity.

RS --

50D

ACCUM

+21%$697K$578K

KLRAKailera's IPO prospectus describes a clinical-stage company built around a multi-asset obesity pipeline, including injectable and oral incretin candidates.

RS --

+148%$23.5M$9.5M

RHHBYRoche reports Phase 2 results for CT-388, an investigational GLP-1/GIP receptor agonist developed for obesity.

RS --

------

Loading…

Members19 tickers

Members19 tickers

Members_{19 tickers}

Members_{19 tickers}